LFCR

Business Context and Reporting Period

Lifecore Biomedical, Inc. (LFCR) is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and hyaluronic acid (HA) manufacturing. This Form 10-Q covers the fiscal quarter and six months ended November 24, 2024. The Company operates as a single reportable segment and is classified as an Accelerated Filer and Smaller Reporting Company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 8% ($2.4 million) for the quarter and 5% ($2.6 million) for the six-month period compared to the prior year. CDMO revenue grew 8% in the quarter, while HA manufacturing revenue grew 7%.
• Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased significantly, rising 19% ($1.8 million) in the quarter and 40% ($7.4 million) for the six months. This was driven by a $1.8 million increase in stock-based compensation (quarter) and $4.4 million in professional fees (six months), including legal fees related to Yucatan Foods litigation.
• Non-Operating Items: The Company recorded a $1.2 million gain from the change in fair value of the debt derivative liability in the quarter, compared to a $20.7 million gain in the prior year quarter. Interest expense increased due to amortization of debt discounts on the Alcon term loan.
• Capital Structure: In October 2024, the Company issued 5.9 million shares of common stock for gross proceeds of $24.3 million. This triggered an anti-dilution adjustment to the Convertible Preferred Stock, resulting in a $2.1 million charge to accumulated deficit.

Guidance, Outlook, and Risks

Management Commentary: Management focuses on three strategic priorities: managing the business development pipeline, maximizing manufacturing capacity, and advancing product commercialization. The Company believes its current cash, potential equity offerings, and credit facility availability are sufficient to finance operations for at least the next twelve months.

Risks and Contingencies:

• Legal Proceedings: A putative class action complaint was filed in July 2024 alleging false statements regarding financial results and internal controls. Additionally, an investor dispute was filed in December 2024 by 22NW Fund, L.P., seeking damages and specific performance regarding the Convertible Preferred Stock.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of November 24, 2024, due to material weaknesses in internal control over financial reporting previously disclosed. Remediation efforts are underway.
• Debt Covenants: The Company is currently in compliance with financial covenants. However, a springing fixed charge ratio covenant applies if liquidity under the Revolving Credit Facility falls below $2.5 million.
• SEC Investigation: The Company is responding to an SEC subpoena issued in February 2024 regarding a financial statement restatement.

Investor Verification Checklist

• Verify the status and potential financial impact of the pending class action lawsuit and the 22NW Fund investor dispute.
• Review the progress of remediation plans for material weaknesses in internal controls over financial reporting.
• Monitor the Company's ability to maintain compliance with debt covenants, specifically the springing fixed charge ratio.
• Assess the sustainability of SG&A expense reductions, particularly regarding professional fees and stock-based compensation.
• Confirm the timeline for the resolution of the SEC subpoena and any potential outcomes.